Results 161 to 170 of about 5,281 (192)

Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy. [PDF]

American Journal of Epidemiology, 2013
MF59-adjuvanted trivalent influenza vaccine (Novartis Vaccines and Diagnostics, Siena, Italy) has been shown to be more effective than nonadjuvanted vaccine in the elderly population. Here we present results from a large-scale, observational, noninterventional, prospective postlicensure study that evaluated the safety of MF59-adjuvanted vaccine in ...
Giovanni Apolone, Domenico Mavilio
exaly   +4 more sources

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates

Vaccine, 2010
MF59 is already known to enhance the breadth of antibody response to mismatched influenza seasonal and avian strains. However, little is known on the effect of MF59 on immunogenicity of influenza vaccines when "apparent" good matching between circulating
Paolo Durando, Emanuele Montomoli, Filippo Ansaldi   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Safety of MF59™ adjuvant

Vaccine, 2008
The need to enhance the immunogenicity of purified subunit antigens has prompted the development of new adjuvants. The adjuvant emulsion MF59 has been tested in animals in combination with different antigens and finally evaluated in humans. It was licensed after the successful outcome of preclinical and clinical testing.
Viola, Schultze, Vicente, D'Agosto, Andreas, Wack, Deborah, Novicki, Juergen, Zorn, Renald, Hennig   +5 more
openaire   +2 more sources

Combination of Microneedles and MF59 Adjuvant as a Simple Approach to Enhance Transcutaneous Immunization

Journal of Biomedical Nanotechnology, 2020
MF59, an oil-in-water nanoemulsion, has been used in licensed seasonal influenza vaccines for many years. Administration of such vaccines by injection is associated with pain and safety issues. Here, we evaluated the potential of administering MF59 via a transcutaneous route with antigen loading (either encapsulated into or mixed with MF59) to intact ...
Congcong Zhu
exaly   +3 more sources

Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1

New England Journal of Medicine, 2008
The authors report on an open-label study of an MF59-adjuvanted vaccine against avian influenza.
Stephenson, I, Nicholson, KG, Hoschler, K, Zambon, MC, Hancock, K, DeVos, J, Katz, JM, Praus, M, Banzhoff, A   +8 more
openaire   +3 more sources

MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines

1995
MF59 is a safe, practical, and potent adjuvant for use with human vaccines. The formulation is easily manufactured, may be sterilized by filtration, and is both compatible and efficacious with all antigens tested to date. MF59 has been shown to be a potent stimulator of cellular and humoral responses to subunit antigens in both animal models and ...
G, Ott, G L, Barchfeld, D, Chernoff, R, Radhakrishnan, P, van Hoogevest, G, Van Nest   +5 more
openaire   +2 more sources

MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)

Pharmaceutical Research, 2009
The effectiveness of vaccines depends on the age and immunocompetence of the vaccinee. Conventional non-adjuvanted influenza vaccines are suboptimal in the elderly and vaccines with improved ability to prevent influenza are required. The TLR4 agonist E6020, either given alone or co-delivered with MF59, was evaluated and compared to MF59 and the TLR9 ...
Barbara C, Baudner, Vanessa, Ronconi, Daniele, Casini, Marco, Tortoli, Jina, Kazzaz, Manmohan, Singh, Lynn D, Hawkins, Andreas, Wack, Derek T, O'Hagan   +8 more
openaire   +2 more sources

Exposure to MF59-adjuvanted influenza vaccines during pregnancy—A retrospective analysis

Vaccine, 2010
Pregnant women are at increased risk for complications and death associated with pandemic H1N1 influenza infection and they are prioritized for vaccination by public health authorities. Few data are available on the safety of adjuvants as components of pandemic vaccines that could be given systematically to pregnant women.
Ralf Clemens, Theodore F Tsai, Deborah Novicki   +2 more
exaly   +3 more sources

Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly

Vaccine, 2007
In a randomized, observer-blind, three-arm, parallel group, multi-centre trial including 386 elderly subjects in four countries, the immunogenicity and safety was studied of three different trivalent inactivated surface antigen (subunit) influenza vaccine types: a conventional subunit influenza vaccine (SIV, brand: Influvac and two newer vaccines: a ...
Iris, de Bruijn, Ingo, Meyer, Lisya, Gerez, Jos, Nauta, Katinka, Giezeman, Bram, Palache   +5 more
openaire   +2 more sources

Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles

Molecular Medicine Today, 1997
Vaccines produced by recombinant DNA technology are safer than 'traditional' vaccines but they are often poorly immunogenic, requiring adjuvants to enhance their immunogenicity. Particulate adjuvants of defined dimensions (< 5 microns) have been shown to be effective in enhancing the immunogenicity of 'weak' antigens in animal models.
D T, O'Hagan, G S, Ott, G, Van Nest
openaire   +2 more sources